The September Jobs Report was released this morning, showing 136,000 jobs added, and a 2.9% rise in average hourly wages year-over-year. Yahoo Finance's Alexis Christoforous, Brian Sozzi, and Jared Blikre are joined by David Nelson, Belpointe Asset Management Chief Strategist, and Michelle Meyer, Chief U.S. Economist at Bank of America Merrill Lynch, to discuss.
Uncertainty is the word of the day, in reference to the near-term economic future. Sentiment will hinge on the inflation numbers due out next week. March’s figure rose to 3.5%, and April’s job numbers showed a marked slowing in the labor market; that combination has stoked fears of stagflation. But – corporate earnings from Q1 are beating expectations, and the stock market has taken a turn for the better with the S&P 500 closing just below 5,200 yesterday. Economic strategists are still optimist
The Bill and Melinda Gates Foundation Trust outperformed the S&P 500 by a wide margin over the past three years, in part because of these two stocks.
If you're taking a required minimum distribution from an IRA, 401(k) or other tax-deferred account and don't need the money to cover living expenses, where should you stash that unneeded cash? Investors now need to start taking RMDs at age 73 or, if they were born after 1960, at age 75. Depending on the balances of […] The post Can I Use My RMDs to Transfer Money Into My Roth IRA? appeared first on SmartReads by SmartAsset.
Social Security payments may be subject to cuts. Here's what the timing looks like.
These supercharged energy income stocks -- with an average yield of 9.87% -- can really fatten your pocketbook.
High-water price targets from a trio of Wall Street pundits imply three diminutive companies can skyrocket 223% to 557%.
Investing in cheap stocks brings unique risks because there is usually a reason the companies are undervalued.
"Investors' expectation that the Fed would nip a recession in the bud by easing means that the Fed Put is back," Ed Yardeni said.
Pfizer stock ran up to its 50-day line after the company reported better-than-expected sales and profit. Is PFE stock a buy?
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?